<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26600609</article-id><article-id pub-id-type="pmc">4645434</article-id><article-id pub-id-type="publisher-id">BLT.14.151290</article-id><article-id pub-id-type="doi">10.2471/BLT.14.151290</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Disponibilit&#x000e9; et accessibilit&#x000e9; financi&#x000e8;re des nouveaux m&#x000e9;dicaments dans les pays d'Am&#x000e9;rique latine o&#x000f9; ont &#x000e9;t&#x000e9; men&#x000e9;s des essais cliniques pivots</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">La disponibilidad y asequibilidad de nuevos medicamentos en los pa&#x000ed;ses de Am&#x000e9;rica Latina en los que se llevaron a cabo ensayos cl&#x000ed;nicos decisivos</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00627;&#x00631;&#x00628; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00648;&#x00631;&#x0064a;&#x00629; </trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x0041d;&#x00430;&#x0043b;&#x00438;&#x00447;&#x00438;&#x00435; &#x00438; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043d;&#x0043e;&#x00432;&#x0044b;&#x00445; &#x0043b;&#x00435;&#x0043a;&#x00430;&#x00440;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00441;&#x00440;&#x00435;&#x00434;&#x00441;&#x00442;&#x00432; &#x00432; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445; &#x0041b;&#x00430;&#x00442;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00410;&#x0043c;&#x00435;&#x00440;&#x00438;&#x0043a;&#x00438;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x0044f;&#x00442;&#x00441;&#x0044f; &#x0043e;&#x0043f;&#x0043e;&#x00440;&#x0043d;&#x0044b;&#x00435; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00435; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">N&#x000fa;ria Homedes &#x00026; Antonio Ugalde</alt-title><alt-title alt-title-type="title-running-head">Clinical trials in Latin America</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Homedes</surname><given-names>N&#x000fa;ria</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ugalde</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><aff id="aff1"><label>a</label>Houston Health Science Center, School of Public Health, El Paso Regional Campus, University of Texas, 1101 North Campbell Street, El Paso 79902, United States of America (USA).</aff><aff id="aff2"><label>b</label>Department of Sociology, University of Texas at Austin, Texas, <country>USA</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to N&#x000fa;ria Homedes (email: <email xlink:href="nhomedes@gmail.com">nhomedes@gmail.com</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>29</day><month>7</month><year>2015</year></pub-date><volume>93</volume><issue>10</issue><fpage>674</fpage><lpage>683</lpage><history><date date-type="received"><day>05</day><month>12</month><year>2014</year></date><date date-type="rev-recd"><day>30</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>06</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>(c) 2015 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To assess whether new pharmaceutical products approved by the United States Food and Drug Administration (FDA) in 2011 and 2012 were registered, commercialized and sold at affordable prices in the Latin American countries where they were tested.</p></sec><sec><title>Methods</title><p>We obtained a list of new molecular entities (new pharmaceutical products) approved by the FDA in 2011 and 2012. FDA medical reviews indicated the countries where pivotal clinical trials had been conducted. The registration status of the products was obtained from pharmaceutical registers; pharmaceutical companies confirmed their availability in national markets and local pricing observatories provided the price of medicines in retail pharmacies. Affordability was assessed as the cost of a course of treatment as a proportion of monthly income. Information on safety and efficacy was gathered from independent drug bulletins.</p></sec><sec><title>Findings</title><p>Of an expected 114 registrations, if the 33 products had been registered in all the countries where tested, only 68 (60%) were completed. Eight products were registered and commercialized in all countries but 10 had not been registered in any of the countries. With one exception, products for which we obtained pricing information (<italic>n</italic>&#x02009;=&#x02009;18) cost more than the monthly minimum wage in all countries and 12 products cost at least five times the monthly minimum wage.</p></sec><sec><title>Conclusion</title><p>Many pharmaceutical products tested in Latin America are unavailable and/or unaffordable to most of the population. Ethical review committees should consider the local affordability and therapeutic relevance of new products as additional criteria for the approval of clinical trials. Finally, clinical trials have opportunity costs that need to be assessed.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9;</title><sec><title>Objectif</title><p>&#x000c9;valuer si les nouveaux produits pharmaceutiques approuv&#x000e9;s par la <italic>Food and Drug Administration</italic> (FDA) des &#x000c9;tats-Unis en 2011 et 2012 ont &#x000e9;t&#x000e9; homologu&#x000e9;s, mis sur le march&#x000e9; et vendus &#x000e0; des prix abordables dans les pays d'Am&#x000e9;rique latine o&#x000f9; ils ont &#x000e9;t&#x000e9; test&#x000e9;s.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous nous sommes procur&#x000e9; la liste des nouvelles entit&#x000e9;s mol&#x000e9;culaires (nouveaux produits pharmaceutiques) approuv&#x000e9;es par la FDA en 2011 et 2012. Les comptes-rendus m&#x000e9;dicaux de la FDA indiquaient les pays dans lesquels des essais cliniques pivots avaient &#x000e9;t&#x000e9; men&#x000e9;s. Le statut des produits en mati&#x000e8;re d'homologation nous a &#x000e9;t&#x000e9; r&#x000e9;v&#x000e9;l&#x000e9; par les registres pharmaceutiques; les soci&#x000e9;t&#x000e9;s pharmaceutiques ont confirm&#x000e9; la disponibilit&#x000e9; des produits sur les march&#x000e9;s nationaux et les observatoires locaux des prix nous ont communiqu&#x000e9; le prix des m&#x000e9;dicaments dans les pharmacies de d&#x000e9;tail. Leur accessibilit&#x000e9; financi&#x000e8;re a &#x000e9;t&#x000e9; &#x000e9;valu&#x000e9;e au regard du revenu mensuel. Des informations sur leur innocuit&#x000e9; et leur efficacit&#x000e9; ont &#x000e9;t&#x000e9; recueillies dans des bulletins pharmaceutiques ind&#x000e9;pendants.</p></sec><sec><title>R&#x000e9;sultats</title><p>Sur les 114&#x000a0;homologations escompt&#x000e9;es si les 33&#x000a0;produits avaient &#x000e9;t&#x000e9; homologu&#x000e9;s dans tous les pays o&#x000f9; ils ont &#x000e9;t&#x000e9; test&#x000e9;s, seules 68 (60%) &#x000e9;taient accord&#x000e9;es. Huit produits &#x000e9;taient homologu&#x000e9;s et commercialis&#x000e9;s dans tous les pays, mais 10 n'avaient &#x000e9;t&#x000e9; homologu&#x000e9;s dans aucun des pays. &#x000c0; une exception pr&#x000e8;s, les produits pour lesquels nous avons obtenu des informations tarifaires (<italic>n</italic>&#x02009;=&#x02009;18) ont un prix sup&#x000e9;rieur au salaire minimum mensuel dans tous les pays et 12&#x000a0;produits co&#x000fb;tent au moins cinq fois plus que le salaire minimum mensuel.</p></sec><sec><title>Conclusion</title><p>De nombreux produits pharmaceutiques test&#x000e9;s en Am&#x000e9;rique latine sont indisponibles et/ou inaccessibles financi&#x000e8;rement pour la majeure partie de la population. Les comit&#x000e9;s d'&#x000e9;thique devraient envisager de prendre en compte l'accessibilit&#x000e9; financi&#x000e8;re et l'int&#x000e9;r&#x000ea;t th&#x000e9;rapeutique des nouveaux produits au niveau local comme crit&#x000e8;res suppl&#x000e9;mentaires d'approbation des essais cliniques. Enfin, les essais cliniques ont des co&#x000fb;ts d'opportunit&#x000e9; qui doivent &#x000ea;tre &#x000e9;valu&#x000e9;s.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Evaluar si los nuevos productos farmac&#x000e9;uticos aprobados por la Administraci&#x000f3;n de Alimentos y Medicamentos (FDA) de los Estados Unidos en 2011 y 2012 fueron registrados, comercializados y vendidos a precios asequibles en los pa&#x000ed;ses de Am&#x000e9;rica Latina en los que se probaron.</p></sec><sec><title>M&#x000e9;todos</title><p>Se obtuvo una lista de las nuevas entidades moleculares (los nuevos productos farmac&#x000e9;uticos) aprobadas por la FDA en 2011 y 2012. Los an&#x000e1;lisis m&#x000e9;dicos de la FDA indicaron los pa&#x000ed;ses en los que se hab&#x000ed;an llevado a cabo los ensayos cl&#x000ed;nicos decisivos. El estado del registro de los productos se obtuvo de los registros farmac&#x000e9;uticos; las empresas farmac&#x000e9;uticas confirmaron su disponibilidad en los mercados nacionales y los observatorios de precios proporcionaron el precio de los medicamentos en farmacias minoristas. La asequibilidad se evalu&#x000f3; como el costo de un ciclo de tratamiento en proporci&#x000f3;n a los ingresos mensuales. La informaci&#x000f3;n sobre seguridad y eficacia se obtuvo de boletines independientes de medicamentos.</p></sec><sec><title>Resultados</title><p>De los 114 registros esperados si los 33 productos se hubieran registrado en todos los pa&#x000ed;ses en los que se hab&#x000ed;an probado, solo se completaron 68 (el 60%). Se registraron y comercializaron ocho productos en todos los pa&#x000ed;ses, pero 10 no hab&#x000ed;an sido registrados en ninguno de los pa&#x000ed;ses. Con una excepci&#x000f3;n, los productos sobre los que obtuvimos informaci&#x000f3;n sobre precios (<italic>n</italic>&#x02009;=&#x02009;18) costaban m&#x000e1;s que el sueldo m&#x000ed;nimo mensual en todos los pa&#x000ed;ses y 12 productos costaban al menos cinco veces el sueldo m&#x000ed;nimo mensual.</p></sec><sec><title>Conclusi&#x000f3;n</title><p>Varios productos farmac&#x000e9;uticos probados en Am&#x000e9;rica Latina no se encuentran disponibles o no son asequibles para la mayor parte de la poblaci&#x000f3;n. Los comit&#x000e9;s de revisi&#x000f3;n &#x000e9;tica deber&#x000ed;an considerar la asequibilidad local y la relevancia terap&#x000e9;utica de los nuevos productos como un criterio adicional a la hora de aprobar ensayos cl&#x000ed;nicos. Finalmente, los ensayos cl&#x000ed;nicos tienen costes de oportunidad que necesitan ser evaluados. </p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; <bold/>&#x00644;&#x00644;&#x0062a;&#x00623;&#x00643;&#x0062f; &#x00645;&#x00646; &#x00623;&#x00646; &#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062c;&#x0062f;&#x0064a;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00645;&#x00639;&#x0062a;&#x00645;&#x0062f;&#x00629; &#x00645;&#x00646; &#x00625;&#x0062f;&#x00627;&#x00631;&#x00629; &#x00627;&#x00644;&#x00623;&#x0063a;&#x00630;&#x0064a;&#x00629; &#x00648;&#x00627;&#x00644;&#x00639;&#x00642;&#x00627;&#x00642;&#x0064a;&#x00631; &#x00628;&#x00627;&#x00644;&#x00648;&#x00644;&#x00627;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062a;&#x0062d;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;&#x00629; (FDA) &#x00641;&#x0064a; &#x00639;&#x00627;&#x00645;&#x0064a; 2011 &#x00648;2012&#x0060c; &#x00642;&#x0062f; &#x0062a;&#x00645; &#x0062a;&#x00633;&#x0062c;&#x0064a;&#x00644;&#x00647;&#x00627; &#x00648;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645;&#x00647;&#x00627; &#x0062a;&#x0062c;&#x00627;&#x00631;&#x0064a;&#x00627;&#x0064b; &#x00648;&#x00628;&#x0064a;&#x00639;&#x00647;&#x00627; &#x00628;&#x00623;&#x00633;&#x00639;&#x00627;&#x00631; &#x00645;&#x0064a;&#x00633;&#x00648;&#x00631;&#x00629; &#x00641;&#x0064a; &#x0062f;&#x00648;&#x00644; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x00627; &#x00627;&#x00644;&#x00644;&#x00627;&#x0062a;&#x0064a;&#x00646;&#x0064a;&#x00629; &#x0062d;&#x0064a;&#x0062b; &#x0062a;&#x00645; &#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00647;&#x00627;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x0062d;&#x00635;&#x00644;&#x00646;&#x00627; &#x00639;&#x00644;&#x00649; &#x00642;&#x00627;&#x00626;&#x00645;&#x00629; &#x00628;&#x00627;&#x00644;&#x00643;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062c;&#x00632;&#x0064a;&#x00626;&#x0064a;&#x00629; (&#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062c;&#x0062f;&#x0064a;&#x0062f;&#x00629;) &#x00627;&#x00644;&#x00645;&#x00639;&#x0062a;&#x00645;&#x0062f;&#x00629; &#x00645;&#x00646; &#x00625;&#x0062f;&#x00627;&#x00631;&#x00629; &#x00627;&#x00644;&#x00623;&#x0063a;&#x00630;&#x0064a;&#x00629; &#x00648;&#x00627;&#x00644;&#x00639;&#x00642;&#x00627;&#x00642;&#x0064a;&#x00631; &#x00641;&#x0064a; &#x00639;&#x00627;&#x00645;&#x0064a; 2011 &#x00648;2012. &#x00648;&#x00623;&#x00648;&#x00636;&#x0062d;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00629; &#x00644;&#x00625;&#x0062f;&#x00627;&#x00631;&#x00629; &#x00627;&#x00644;&#x00623;&#x0063a;&#x00630;&#x0064a;&#x00629; &#x00648;&#x00627;&#x00644;&#x00639;&#x00642;&#x00627;&#x00642;&#x0064a;&#x00631; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00644; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00645; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00627;&#x00631;&#x00628; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00648;&#x00631;&#x0064a;&#x00629; &#x00628;&#x00647;&#x00627;. &#x00643;&#x00645;&#x00627; &#x0062a;&#x00645; &#x00627;&#x00644;&#x0062d;&#x00635;&#x00648;&#x00644; &#x00639;&#x00644;&#x00649; &#x0062d;&#x00627;&#x00644;&#x00629; &#x0062a;&#x00633;&#x0062c;&#x0064a;&#x00644; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00645;&#x00646; &#x00627;&#x00644;&#x00642;&#x00627;&#x00626;&#x00645;&#x0064a;&#x00646; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00633;&#x0062c;&#x0064a;&#x00644; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00627;&#x00626;&#x0064a;&#x0061b; &#x00648;&#x00623;&#x00643;&#x0062f;&#x0062a; &#x00634;&#x00631;&#x00643;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x0062a;&#x00648;&#x00627;&#x00641;&#x00631; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00623;&#x00633;&#x00648;&#x00627;&#x00642; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00644;&#x0064a;&#x00629;&#x0060c; &#x00643;&#x00645;&#x00627; &#x00623;&#x00641;&#x00627;&#x0062f;&#x0062a; &#x00627;&#x00644;&#x0062c;&#x00647;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00645;&#x00639;&#x00646;&#x0064a;&#x00629; &#x00628;&#x00645;&#x00631;&#x00627;&#x00642;&#x00628;&#x00629; &#x00627;&#x00644;&#x00623;&#x00633;&#x00639;&#x00627;&#x00631;&#x0060c; &#x00628;&#x00623;&#x00633;&#x00639;&#x00627;&#x00631; &#x00627;&#x00644;&#x00623;&#x0062f;&#x00648;&#x0064a;&#x00629; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00635;&#x0064a;&#x0062f;&#x00644;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x0062a;&#x00648;&#x00644;&#x00649; &#x00628;&#x0064a;&#x00639;&#x00647;&#x00627; &#x00628;&#x00627;&#x00644;&#x0062a;&#x0062c;&#x00632;&#x00626;&#x00629;. &#x00648;&#x0062a;&#x00645; &#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x00645;&#x00639;&#x00642;&#x00648;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00623;&#x00633;&#x00639;&#x00627;&#x00631; &#x00639;&#x00644;&#x00649; &#x00623;&#x00646;&#x00647;&#x00627; &#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x0062f;&#x00648;&#x00631;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00628;&#x00627;&#x00639;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00647;&#x00627; &#x00646;&#x00633;&#x00628;&#x00629; &#x00645;&#x00646; &#x00627;&#x00644;&#x0062f;&#x0062e;&#x00644; &#x00627;&#x00644;&#x00634;&#x00647;&#x00631;&#x0064a;. &#x00648;&#x0062a;&#x00645; &#x0062c;&#x00645;&#x00639; &#x00628;&#x00639;&#x00636; &#x00627;&#x00644;&#x00645;&#x00639;&#x00644;&#x00648;&#x00645;&#x00627;&#x0062a; &#x00639;&#x00646; &#x00633;&#x00644;&#x00627;&#x00645;&#x00629; &#x00648;&#x00643;&#x00641;&#x00627;&#x00621;&#x00629; &#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00645;&#x00646; &#x0062e;&#x00644;&#x00627;&#x00644; &#x00627;&#x00644;&#x00646;&#x00634;&#x00631;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00642;&#x00644;&#x00629; &#x00627;&#x00644;&#x00645;&#x0062a;&#x00639;&#x00644;&#x00642;&#x00629; &#x00628;&#x00627;&#x00644;&#x00639;&#x00642;&#x00627;&#x00642;&#x0064a;&#x00631;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00625;&#x00630;&#x00627; &#x00645;&#x00627; &#x0062a;&#x00645; &#x0062a;&#x00633;&#x0062c;&#x0064a;&#x00644; 33 &#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0064b; &#x00641;&#x0064a; &#x00643;&#x00644; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00644; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00645; &#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631; &#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00628;&#x00647;&#x00627;&#x0060c; &#x00648;&#x00630;&#x00644;&#x00643; &#x00645;&#x00646; &#x00628;&#x0064a;&#x00646; 114 &#x00639;&#x00645;&#x00644;&#x0064a;&#x00629; &#x0062a;&#x00633;&#x0062c;&#x0064a;&#x00644; &#x00645;&#x0062a;&#x00648;&#x00642;&#x00639;&#x00629;&#x0060c; &#x00641;&#x00625;&#x00646; &#x00639;&#x00645;&#x00644;&#x0064a;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x00633;&#x0062c;&#x0064a;&#x00644; &#x00627;&#x00644;&#x00645;&#x00643;&#x0062a;&#x00645;&#x00644;&#x00629; &#x0062a;&#x00628;&#x00644;&#x0063a; 68 &#x00639;&#x00645;&#x00644;&#x0064a;&#x00629; <styled-content style-type="direction" style="direction:ltr;">(60%</styled-content>) &#x00641;&#x00642;&#x00637;. &#x00648;&#x0062a;&#x00645; &#x0062a;&#x00633;&#x0062c;&#x0064a;&#x00644; &#x0062b;&#x00645;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00648;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645;&#x00647;&#x00627; &#x0062a;&#x0062c;&#x00627;&#x00631;&#x0064a;&#x0064b;&#x00627; &#x00641;&#x0064a; &#x00643;&#x00627;&#x00641;&#x00629; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00644;&#x0060c; &#x00648;&#x00644;&#x00643;&#x00646; &#x00644;&#x00645; &#x0064a;&#x0062a;&#x00645; &#x0062a;&#x00633;&#x0062c;&#x0064a;&#x00644; 10 &#x00645;&#x00646;&#x00647;&#x00627; &#x00641;&#x0064a; &#x00623;&#x0064a;&#x00629; &#x0062f;&#x00648;&#x00644;&#x00629;. &#x00648;&#x00628;&#x00644;&#x0063a;&#x0062a; &#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062d;&#x00635;&#x00644;&#x00646;&#x00627; &#x00639;&#x00644;&#x00649; &#x00645;&#x00639;&#x00644;&#x00648;&#x00645;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00623;&#x00633;&#x00639;&#x00627;&#x00631; &#x00628;&#x00634;&#x00623;&#x00646;&#x00647;&#x00627; (&#x00627;&#x00644;&#x00639;&#x0062f;&#x0062f; = 18) &#x00645;&#x00627; &#x0064a;&#x00632;&#x0064a;&#x0062f; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062d;&#x0062f; &#x00627;&#x00644;&#x00623;&#x0062f;&#x00646;&#x00649; &#x00644;&#x00644;&#x00631;&#x00627;&#x0062a;&#x00628; &#x00627;&#x00644;&#x00634;&#x00647;&#x00631;&#x0064a; &#x00641;&#x0064a; &#x0062c;&#x00645;&#x0064a;&#x00639; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00644;&#x0060c; &#x00628;&#x0064a;&#x00646;&#x00645;&#x00627; &#x00628;&#x00644;&#x0063a;&#x0062a; &#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; 12 &#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0064b; &#x00645;&#x00627; &#x0064a;&#x00633;&#x00627;&#x00648;&#x0064a; &#x0062e;&#x00645;&#x00633; &#x00623;&#x00636;&#x00639;&#x00627;&#x00641; &#x00627;&#x00644;&#x0062d;&#x0062f; &#x00627;&#x00644;&#x00623;&#x0062f;&#x00646;&#x00649; &#x00644;&#x00644;&#x00631;&#x00627;&#x0062a;&#x00628; &#x00627;&#x00644;&#x00634;&#x00647;&#x00631;&#x0064a;&#x0060c; &#x00648;&#x00630;&#x00644;&#x00643; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062b;&#x00646;&#x00627;&#x00621; &#x00645;&#x00646;&#x0062a;&#x0062c; &#x00648;&#x0062d;&#x0064a;&#x0062f;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00644;&#x00627; &#x0064a;&#x0062a;&#x00648;&#x00627;&#x00641;&#x00631; &#x00627;&#x00644;&#x00643;&#x0062b;&#x0064a;&#x00631; &#x00645;&#x00646; &#x00627;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062f;&#x00648;&#x00627;&#x00626;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x0064a; &#x0062a;&#x00645; &#x00627;&#x0062e;&#x0062a;&#x00628;&#x00627;&#x00631;&#x00647;&#x00627; &#x00641;&#x0064a; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x00627; &#x00627;&#x00644;&#x00644;&#x00627;&#x0062a;&#x0064a;&#x00646;&#x0064a;&#x00629; &#x00648;/&#x00623;&#x00648; &#x00644;&#x00627; &#x0064a;&#x00645;&#x00643;&#x00646; &#x00627;&#x00644;&#x0062d;&#x00635;&#x00648;&#x00644; &#x00639;&#x00644;&#x0064a;&#x00647;&#x00627; &#x00628;&#x00623;&#x00633;&#x00639;&#x00627;&#x00631; &#x00645;&#x00639;&#x00642;&#x00648;&#x00644;&#x00629; &#x00644;&#x00645;&#x00639;&#x00638;&#x00645; &#x00633;&#x00643;&#x00627;&#x00646; &#x00647;&#x00630;&#x00647; &#x00627;&#x00644;&#x00645;&#x00646;&#x00637;&#x00642;&#x00629;. &#x00648;&#x0064a;&#x0062c;&#x00628; &#x00639;&#x00644;&#x00649; &#x00644;&#x0062c;&#x00627;&#x00646; &#x00627;&#x00644;&#x00645;&#x00631;&#x00627;&#x0062c;&#x00639;&#x00629; &#x00627;&#x00644;&#x00623;&#x0062e;&#x00644;&#x00627;&#x00642;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00646;&#x00638;&#x00631; &#x00641;&#x0064a; &#x00645;&#x0062f;&#x00649; &#x00645;&#x00639;&#x00642;&#x00648;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00623;&#x00633;&#x00639;&#x00627;&#x00631; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00645;&#x00633;&#x0062a;&#x00648;&#x00649; &#x00627;&#x00644;&#x00645;&#x0062d;&#x00644;&#x0064a; &#x00648;&#x00627;&#x00644;&#x00645;&#x00644;&#x00627;&#x00621;&#x00645;&#x00629; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c;&#x0064a;&#x00629; &#x00644;&#x00644;&#x00645;&#x00646;&#x0062a;&#x0062c;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062c;&#x0062f;&#x0064a;&#x0062f;&#x00629; &#x00628;&#x00627;&#x00639;&#x0062a;&#x00628;&#x00627;&#x00631; &#x00630;&#x00644;&#x00643; &#x00645;&#x00639;&#x0064a;&#x00627;&#x00631; &#x00625;&#x00636;&#x00627;&#x00641;&#x0064a; &#x00644;&#x00627;&#x00639;&#x0062a;&#x00645;&#x00627;&#x0062f; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00627;&#x00631;&#x00628; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629;. &#x00648;&#x00623;&#x0062e;&#x0064a;&#x00631;&#x0064b;&#x00627;&#x0060c; &#x0062a;&#x0062d;&#x0062a;&#x00627;&#x0062c; &#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00641;&#x00631;&#x00635; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00627;&#x00631;&#x00628; &#x00627;&#x00644;&#x00633;&#x00631;&#x0064a;&#x00631;&#x0064a;&#x00629; &#x00625;&#x00644;&#x00649; &#x00627;&#x00644;&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645;. </p></sec></trans-abstract><trans-abstract xml:lang="es"><p>&#x08fdb;&#x0884c;&#x04e86;&#x05173;&#x0952e;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x07684;&#x062c9;&#x04e01;&#x07f8e;&#x06d32;&#x056fd;&#x05bb6;&#x05bf9;&#x065b0;&#x0836f;&#x054c1;&#x07684;&#x053ef;&#x05f97;&#x06027;&#x0548c;&#x08d1f;&#x062c5;&#x080fd;&#x0529b;</p></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x08bc4;&#x04f30;&#x07f8e;&#x056fd;&#x098df;&#x054c1;&#x0836f;&#x07269;&#x07ba1;&#x07406;&#x05c40;&#x000a0;(FDA)&#x000a0;2011&#x000a0;&#x05e74;&#x0548c;&#x000a0;2012&#x000a0;&#x05e74;&#x06279;&#x051c6;&#x07684;&#x03001;&#x05728;&#x062c9;&#x04e01;&#x07f8e;&#x06d32;&#x056fd;&#x05bb6;&#x08fdb;&#x0884c;&#x08bd5;&#x09a8c;&#x07684;&#x065b0;&#x0836f;&#x054c1;&#x0662f;&#x05426;&#x05df2;&#x06ce8;&#x0518c;&#x04e14;&#x05546;&#x054c1;&#x05316;&#x0ff0c;&#x0662f;&#x05426;&#x04ee5;&#x08d1f;&#x062c5;&#x05f97;&#x08d77;&#x07684;&#x04ef7;&#x0683c;&#x051fa;&#x0552e;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x083b7;&#x05f97;&#x04e86;&#x000a0;(FDA)&#x000a0;2011&#x000a0;&#x05e74;&#x0548c;&#x000a0;2012&#x000a0;&#x05e74;&#x06279;&#x051c6;&#x07684;&#x065b0;&#x05206;&#x05b50;&#x05b9e;&#x04f53;&#x0836f;&#x07269;&#x0ff08;&#x065b0;&#x0836f;&#x054c1;&#x0ff09;&#x07684;&#x06e05;&#x05355;&#x03002;(FDA)&#x000a0;&#x0533b;&#x07597;&#x05ba1;&#x067e5;&#x08868;&#x0660e;&#x08fdb;&#x0884c;&#x05173;&#x0952e;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x07684;&#x056fd;&#x05bb6;&#x03002; &#x0836f;&#x054c1;&#x07684;&#x06ce8;&#x0518c;&#x072b6;&#x06001;&#x04ece;&#x0836f;&#x054c1;&#x06ce8;&#x0518c;&#x05904;&#x083b7;&#x05f97;&#x0ff0c;&#x05236;&#x0836f;&#x0516c;&#x053f8;&#x05728;&#x05168;&#x056fd;&#x05e02;&#x0573a;&#x0786e;&#x05b9a;&#x0836f;&#x054c1;&#x07684;&#x053ef;&#x05f97;&#x06027;&#x0ff0c;&#x05f53;&#x05730;&#x04ef7;&#x0683c;&#x076d1;&#x06d4b;&#x07ad9;&#x063d0;&#x04f9b;&#x0836f;&#x054c1;&#x05728;&#x096f6;&#x0552e;&#x0836f;&#x0623f;&#x07684;&#x04ef7;&#x0683c;&#x03002; &#x08d1f;&#x062c5;&#x080fd;&#x0529b;&#x06309;&#x07167;&#x04e00;&#x04e2a;&#x07597;&#x07a0b;&#x07684;&#x08d39;&#x07528;&#x05728;&#x06708;&#x06536;&#x05165;&#x04e2d;&#x06240;&#x05360;&#x06bd4;&#x04f8b;&#x08fdb;&#x0884c;&#x08bc4;&#x04f30;&#x03002; &#x05b89;&#x05168;&#x0548c;&#x07597;&#x06548;&#x04fe1;&#x0606f;&#x04ece;&#x072ec;&#x07acb;&#x07684;&#x0836f;&#x07269;&#x0516c;&#x0544a;&#x06536;&#x096c6;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x05982;&#x0679c;&#x000a0;33&#x000a0;&#x079cd;&#x0836f;&#x054c1;&#x05df2;&#x07ecf;&#x05728;&#x08bd5;&#x09a8c;&#x07684;&#x06240;&#x06709;&#x056fd;&#x05bb6;&#x06ce8;&#x0518c;&#x08fc7;&#x0ff0c;&#x05728;&#x09884;&#x0671f;&#x07684;&#x000a0;114&#x000a0;&#x04e2a;&#x06ce8;&#x0518c;&#x056fd;&#x05bb6;&#x04e2d;&#x0ff0c;&#x053ea;&#x06709;&#x000a0;68&#x000a0;&#x04e2a;&#x000a0;(60%) &#x000a0;&#x05df2;&#x05b8c;&#x06210;&#x03002; 8&#x000a0;&#x079cd;&#x0836f;&#x054c1;&#x05728;&#x06240;&#x06709;&#x056fd;&#x05bb6;&#x06ce8;&#x0518c;&#x08fc7;&#x0548c;&#x05546;&#x054c1;&#x05316;&#x0ff0c;&#x04f46;&#x06709;&#x000a0;10&#x000a0;&#x079cd;&#x0836f;&#x054c1;&#x08fd8;&#x0672a;&#x05728;&#x04efb;&#x04f55;&#x056fd;&#x05bb6;&#x06ce8;&#x0518c;&#x08fc7;&#x03002; &#x04ece;&#x06211;&#x04eec;&#x083b7;&#x05f97;&#x07684;&#x04ef7;&#x0683c;&#x04fe1;&#x0606f;&#x000a0;(<italic>n</italic>&#x02009;=&#x02009;18)&#x000a0;&#x06765;&#x0770b;&#x0ff0c;&#x09664;&#x04e86;&#x04e00;&#x079cd;&#x04f8b;&#x05916;&#x0ff0c;&#x06240;&#x06709;&#x056fd;&#x05bb6;&#x07684;&#x0836f;&#x054c1;&#x04ef7;&#x0683c;&#x090fd;&#x08d85;&#x08fc7;&#x04e86;&#x06708;&#x06700;&#x04f4e;&#x06536;&#x05165;&#x0ff0c;&#x06709;&#x000a0;12&#x000a0;&#x079cd;&#x0836f;&#x054c1;&#x07684;&#x04ef7;&#x0683c;&#x081f3;&#x05c11;&#x0662f;&#x06708;&#x06700;&#x04f4e;&#x06536;&#x05165;&#x07684;&#x04e94;&#x0500d;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x08bb8;&#x0591a;&#x05728;&#x062c9;&#x04e01;&#x07f8e;&#x06d32;&#x08bd5;&#x09a8c;&#x07684;&#x0836f;&#x07269;&#x090fd;&#x04e0d;&#x053ef;&#x05f97;&#x04e14;/&#x06216;&#x05927;&#x090e8;&#x05206;&#x04eba;&#x08d1f;&#x062c5;&#x04e0d;&#x08d77;&#x03002; &#x04f26;&#x07406;&#x05ba1;&#x067e5;&#x059d4;&#x05458;&#x04f1a;&#x05e94;&#x08003;&#x08651;&#x065b0;&#x0836f;&#x054c1;&#x07684;&#x05f53;&#x05730;&#x08d1f;&#x062c5;&#x080fd;&#x0529b;&#x0548c;&#x06cbb;&#x07597;&#x076f8;&#x05173;&#x06027;&#x0ff0c;&#x04ee5;&#x06b64;&#x04f5c;&#x04e3a;&#x06279;&#x051c6;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x07684;&#x09644;&#x052a0;&#x06807;&#x051c6;&#x03002; &#x06700;&#x0540e;&#x0ff0c;&#x04e34;&#x05e8a;&#x08bd5;&#x09a8c;&#x06709;&#x09700;&#x08981;&#x08fdb;&#x0884c;&#x08bc4;&#x04f30;&#x07684;&#x0673a;&#x04f1a;&#x06210;&#x0672c;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x0041e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430; &#x00442;&#x0043e;&#x00433;&#x0043e;, &#x00431;&#x0044b;&#x0043b;&#x00438; &#x0043b;&#x00438; &#x00437;&#x00430;&#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0044b;, &#x00432;&#x0044b;&#x0043f;&#x00443;&#x00449;&#x00435;&#x0043d;&#x0044b; &#x00432; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00430;&#x00436;&#x00443; &#x00438; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0044b; &#x0043f;&#x0043e; &#x0043f;&#x00440;&#x00438;&#x00435;&#x0043c;&#x0043b;&#x00435;&#x0043c;&#x0044b;&#x0043c; &#x00446;&#x00435;&#x0043d;&#x00430;&#x0043c; &#x0043d;&#x0043e;&#x00432;&#x0044b;&#x00435; &#x00432;&#x00438;&#x00434;&#x0044b; &#x00444;&#x00430;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00435;&#x00432;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438;, &#x0043e;&#x00434;&#x0043e;&#x00431;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x00423;&#x0043f;&#x00440;&#x00430;&#x00432;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00421;&#x00428;&#x00410; &#x0043f;&#x0043e; &#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00440;&#x0043e;&#x0043b;&#x0044e; &#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; &#x0043f;&#x00438;&#x00449;&#x00435;&#x00432;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00442;&#x0043e;&#x00432; &#x00438; &#x0043b;&#x00435;&#x0043a;&#x00430;&#x00440;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00441;&#x00440;&#x00435;&#x00434;&#x00441;&#x00442;&#x00432; (FDA) &#x00432; 2011 &#x00438; 2012&#x000a0;&#x00433;&#x00433;., &#x00432; &#x00442;&#x00435;&#x00445; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445; &#x0041b;&#x00430;&#x00442;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00410;&#x0043c;&#x00435;&#x00440;&#x00438;&#x0043a;&#x00438;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x00438;&#x00445; &#x00438;&#x00441;&#x0043f;&#x0044b;&#x00442;&#x00430;&#x0043d;&#x00438;&#x0044f;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x0041c;&#x0044b; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x0043b;&#x00438; &#x00441;&#x0043f;&#x00438;&#x00441;&#x0043e;&#x0043a; &#x0043d;&#x0043e;&#x00432;&#x0044b;&#x00445; &#x0043c;&#x0043e;&#x0043b;&#x00435;&#x0043a;&#x00443;&#x0043b;&#x0044f;&#x00440;&#x0043d;&#x0044b;&#x00445; &#x00435;&#x00434;&#x00438;&#x0043d;&#x00438;&#x00446; (&#x0043d;&#x0043e;&#x00432;&#x0043e;&#x00439; &#x00444;&#x00430;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00435;&#x00432;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438;), &#x0043e;&#x00434;&#x0043e;&#x00431;&#x00440;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; FDA &#x00432; 2011 &#x00438; 2012&#x000a0;&#x00433;&#x00433;. &#x00412; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x00438;&#x00445; &#x0043e;&#x00431;&#x00437;&#x0043e;&#x00440;&#x00430;&#x00445; FDA &#x00443;&#x0043a;&#x00430;&#x00437;&#x0044b;&#x00432;&#x00430;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x0044b;, &#x00432; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00445; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x0043e;&#x00434;&#x00438;&#x0043b;&#x00438;&#x00441;&#x0044c; &#x0043e;&#x0043f;&#x0043e;&#x00440;&#x0043d;&#x0044b;&#x00435; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00435; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;. &#x00421;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043e; &#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x0044b; &#x00438;&#x00437; &#x00444;&#x00430;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00435;&#x00432;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00440;&#x00435;&#x00435;&#x00441;&#x00442;&#x00440;&#x0043e;&#x00432;. &#x00424;&#x00430;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00435;&#x00432;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00435; &#x0043a;&#x0043e;&#x0043c;&#x0043f;&#x00430;&#x0043d;&#x00438;&#x00438; &#x0043f;&#x0043e;&#x00434;&#x00442;&#x00432;&#x00435;&#x00440;&#x00434;&#x00438;&#x0043b;&#x00438; &#x0043d;&#x00430;&#x0043b;&#x00438;&#x00447;&#x00438;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438; &#x0043d;&#x00430; &#x0043d;&#x00430;&#x00446;&#x00438;&#x0043e;&#x0043d;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x00440;&#x0044b;&#x0043d;&#x0043a;&#x00430;&#x00445;, &#x00430; &#x0043c;&#x00435;&#x00441;&#x00442;&#x0043d;&#x0044b;&#x00435; &#x00430;&#x00433;&#x00435;&#x0043d;&#x00442;&#x00441;&#x00442;&#x00432;&#x00430; &#x0043f;&#x0043e; &#x0043a;&#x0043e;&#x0043d;&#x00442;&#x00440;&#x0043e;&#x0043b;&#x0044e; &#x00437;&#x00430; &#x00446;&#x00435;&#x0043d;&#x00430;&#x0043c;&#x00438; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00438; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043e; &#x00441;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00442;&#x00435;&#x00445; &#x00438;&#x0043b;&#x00438; &#x00438;&#x0043d;&#x0044b;&#x00445; &#x0043b;&#x00435;&#x0043a;&#x00430;&#x00440;&#x00441;&#x00442;&#x00432; &#x00432; &#x00440;&#x0043e;&#x00437;&#x0043d;&#x00438;&#x00447;&#x0043d;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00430;&#x00436;&#x00435;&#x000a0;(&#x00432; &#x00430;&#x0043f;&#x00442;&#x00435;&#x0043a;&#x00430;&#x00445;). &#x00426;&#x00435;&#x0043d;&#x0043e;&#x00432;&#x00430;&#x0044f; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438; &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x0044b;&#x00432;&#x00430;&#x0043b;&#x00430;&#x00441;&#x0044c; &#x0043d;&#x00430; &#x00442;&#x0043e;&#x0043c;, &#x0043a;&#x00430;&#x0043a;&#x00443;&#x0044e; &#x00434;&#x0043e;&#x0043b;&#x0044e; &#x00441;&#x00442;&#x0043e;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043b;&#x00435;&#x0043a;&#x00430;&#x00440;&#x00441;&#x00442;&#x00432; &#x00437;&#x00430;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x00435;&#x00442; &#x00432; &#x00435;&#x00436;&#x00435;&#x0043c;&#x00435;&#x00441;&#x0044f;&#x00447;&#x0043d;&#x0043e;&#x0043c; &#x00434;&#x0043e;&#x00445;&#x0043e;&#x00434;&#x00435;. &#x0041d;&#x00435;&#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x0043c;&#x0044b;&#x00435; &#x00431;&#x0044e;&#x0043b;&#x0043b;&#x00435;&#x00442;&#x00435;&#x0043d;&#x00438; &#x0043b;&#x00435;&#x0043a;&#x00430;&#x00440;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00441;&#x00440;&#x00435;&#x00434;&#x00441;&#x00442;&#x00432; &#x0043f;&#x00440;&#x00435;&#x00434;&#x0043e;&#x00441;&#x00442;&#x00430;&#x00432;&#x00438;&#x0043b;&#x00438; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00438;&#x0044e; &#x0043e; &#x00431;&#x00435;&#x00437;&#x0043e;&#x0043f;&#x00430;&#x00441;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00438; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043f;&#x00440;&#x00435;&#x0043f;&#x00430;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00432;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00418;&#x00437; &#x0043e;&#x00436;&#x00438;&#x00434;&#x00430;&#x00435;&#x0043c;&#x0044b;&#x00445; 114&#x000a0;&#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00430;&#x00446;&#x00438;&#x00439; &#x0043f;&#x0043e; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430;&#x0043c; &#x00438;&#x00441;&#x0043f;&#x0044b;&#x00442;&#x00430;&#x0043d;&#x00438;&#x0044f; 33&#x000a0;&#x00432;&#x00438;&#x00434;&#x0043e;&#x00432; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438; &#x00432;&#x0043e; &#x00432;&#x00441;&#x00435;&#x00445; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445;-&#x00443;&#x00447;&#x00430;&#x00441;&#x00442;&#x0043d;&#x00438;&#x00446;&#x00430;&#x00445; &#x00438;&#x00441;&#x0043f;&#x0044b;&#x00442;&#x00430;&#x0043d;&#x00438;&#x00439; &#x00444;&#x00430;&#x0043a;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438; &#x00431;&#x0044b;&#x0043b;&#x0043e; &#x00437;&#x00430;&#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0043e; &#x00442;&#x0043e;&#x0043b;&#x0044c;&#x0043a;&#x0043e; 68&#x000a0;&#x0043f;&#x00440;&#x00435;&#x0043f;&#x00430;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00432;&#x000a0;(60%). &#x00412;&#x0043e;&#x00441;&#x00435;&#x0043c;&#x0044c; &#x00432;&#x00438;&#x00434;&#x0043e;&#x00432; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x00437;&#x00430;&#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x0044b; &#x00438; &#x00432;&#x0044b;&#x0043f;&#x00443;&#x00449;&#x00435;&#x0043d;&#x0044b; &#x00432; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00430;&#x00436;&#x00443; &#x00432;&#x0043e; &#x00432;&#x00441;&#x00435;&#x00445; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445;. &#x00414;&#x00435;&#x00441;&#x0044f;&#x00442;&#x0044c; &#x0043f;&#x00440;&#x00435;&#x0043f;&#x00430;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00432; &#x0043d;&#x00435; &#x00438;&#x0043c;&#x00435;&#x0043b;&#x00438; &#x00440;&#x00435;&#x00433;&#x00438;&#x00441;&#x00442;&#x00440;&#x00430;&#x00446;&#x00438;&#x00438; &#x0043d;&#x00438; &#x00432; &#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00439; &#x00438;&#x00437; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;. &#x00417;&#x00430; &#x0043e;&#x00434;&#x0043d;&#x00438;&#x0043c; &#x00438;&#x00441;&#x0043a;&#x0043b;&#x0044e;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c;, &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x0044f;, &#x00434;&#x0043b;&#x0044f; &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x00439; &#x00443;&#x00434;&#x00430;&#x0043b;&#x0043e;&#x00441;&#x0044c; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x00442;&#x0044c; &#x00438;&#x0043d;&#x00444;&#x0043e;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00438;&#x0044e; &#x0043e; &#x00446;&#x00435;&#x0043d;&#x00430;&#x00445;&#x000a0;(<italic>n</italic>&#x000a0;=&#x000a0;18), &#x00441;&#x00442;&#x0043e;&#x00438;&#x0043b;&#x00430; &#x00432;&#x0044b;&#x00448;&#x00435; &#x0043c;&#x00438;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00435;&#x00436;&#x00435;&#x0043c;&#x00435;&#x00441;&#x0044f;&#x00447;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00434;&#x0043e;&#x00445;&#x0043e;&#x00434;&#x00430; &#x00432;&#x0043e; &#x00432;&#x00441;&#x00435;&#x00445; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445;, &#x00430; 12&#x000a0;&#x00432;&#x00438;&#x00434;&#x0043e;&#x00432; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438; &#x00441;&#x00442;&#x0043e;&#x00438;&#x0043b;&#x00438; &#x0043f;&#x0043e; &#x0043c;&#x00435;&#x0043d;&#x0044c;&#x00448;&#x00435;&#x00439; &#x0043c;&#x00435;&#x00440;&#x00435; &#x00432;&#x0043f;&#x0044f;&#x00442;&#x00435;&#x00440;&#x0043e; &#x00431;&#x0043e;&#x0043b;&#x0044c;&#x00448;&#x00435; &#x0043c;&#x00438;&#x0043d;&#x00438;&#x0043c;&#x00430;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00435;&#x00436;&#x00435;&#x0043c;&#x00435;&#x00441;&#x0044f;&#x00447;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00434;&#x0043e;&#x00445;&#x0043e;&#x00434;&#x00430;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x0041c;&#x0043d;&#x0043e;&#x00433;&#x00438;&#x00435; &#x00432;&#x00438;&#x00434;&#x0044b; &#x00444;&#x00430;&#x00440;&#x0043c;&#x00430;&#x00446;&#x00435;&#x00432;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438;, &#x0043f;&#x00440;&#x0043e;&#x00445;&#x0043e;&#x00434;&#x00438;&#x00432;&#x00448;&#x00435;&#x00439; &#x00438;&#x00441;&#x0043f;&#x0044b;&#x00442;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00432; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;&#x00430;&#x00445; &#x0041b;&#x00430;&#x00442;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00439; &#x00410;&#x0043c;&#x00435;&#x00440;&#x00438;&#x0043a;&#x00438;, &#x0043b;&#x00438;&#x00431;&#x0043e; &#x0043e;&#x00442;&#x00441;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x00443;&#x0044e;&#x00442; &#x0043d;&#x00430; &#x00440;&#x0044b;&#x0043d;&#x0043a;&#x00430;&#x00445; &#x0044d;&#x00442;&#x00438;&#x00445; &#x00441;&#x00442;&#x00440;&#x00430;&#x0043d;, &#x0043b;&#x00438;&#x00431;&#x0043e; &#x00438;&#x0043c;&#x00435;&#x0044e;&#x00442;&#x00441;&#x0044f;, &#x0043d;&#x0043e; &#x0043d;&#x00435;&#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0044b; &#x00431;&#x0043e;&#x0043b;&#x0044c;&#x00448;&#x00438;&#x0043d;&#x00441;&#x00442;&#x00432;&#x00443; &#x0043d;&#x00430;&#x00441;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00438;&#x00437;-&#x00437;&#x00430; &#x00446;&#x00435;&#x0043d;&#x0044b;. &#x0041a;&#x0043e;&#x0043c;&#x00438;&#x00442;&#x00435;&#x00442;&#x0044b; &#x0043f;&#x0043e; &#x0044d;&#x00442;&#x00438;&#x0043a;&#x00435; &#x00434;&#x0043e;&#x0043b;&#x00436;&#x0043d;&#x0044b; &#x00443;&#x00447;&#x00438;&#x00442;&#x0044b;&#x00432;&#x00430;&#x00442;&#x0044c; &#x00434;&#x0043e;&#x00441;&#x00442;&#x00443;&#x0043f;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043f;&#x00440;&#x00435;&#x0043f;&#x00430;&#x00440;&#x00430;&#x00442;&#x0043e;&#x00432; &#x0043d;&#x00430; &#x0043c;&#x00435;&#x00441;&#x00442;&#x00430;&#x00445; &#x00438; &#x00442;&#x00435;&#x00440;&#x00430;&#x0043f;&#x00435;&#x00432;&#x00442;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00443;&#x0044e; &#x00440;&#x00435;&#x0043b;&#x00435;&#x00432;&#x00430;&#x0043d;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043d;&#x0043e;&#x00432;&#x0043e;&#x00439; &#x0043f;&#x00440;&#x0043e;&#x00434;&#x00443;&#x0043a;&#x00446;&#x00438;&#x00438; &#x00432; &#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435; &#x00434;&#x0043e;&#x0043f;&#x0043e;&#x0043b;&#x0043d;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x00440;&#x00438;&#x00442;&#x00435;&#x00440;&#x00438;&#x00435;&#x00432; &#x0043f;&#x00440;&#x00438; &#x0043e;&#x00434;&#x0043e;&#x00431;&#x00440;&#x00435;&#x0043d;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;. &#x0041a;&#x00440;&#x0043e;&#x0043c;&#x00435; &#x00442;&#x0043e;&#x00433;&#x0043e;, &#x00441; &#x0043a;&#x0043b;&#x00438;&#x0043d;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438;&#x0043c;&#x00438; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f;&#x0043c;&#x00438; &#x00441;&#x0043e;&#x0043f;&#x00440;&#x0044f;&#x00436;&#x00435;&#x0043d;&#x0044b; &#x00430;&#x0043b;&#x0044c;&#x00442;&#x00435;&#x00440;&#x0043d;&#x00430;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0044b;&#x00435; &#x00438;&#x00437;&#x00434;&#x00435;&#x00440;&#x00436;&#x0043a;&#x00438;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x0044b;&#x00435; &#x00442;&#x00430;&#x0043a;&#x00436;&#x00435; &#x00442;&#x00440;&#x00435;&#x00431;&#x00443;&#x0044e;&#x00442; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438;.</p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The high cost of many new medicines calls into question whether people in low- and middle-income countries will have access to them,<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> yet an increasing number of pivotal trials are carried out in these countries. Pivotal clinical trials are those included in the applications for market authorization or new drug approval documents submitted to regulatory agencies.</p><p>This paper explores two issues: (i)&#x000a0;are new molecular entities (hereafter products) approved by the FDA in 2011 and 2012 available in Latin American countries where the pivotal trials were conducted? and (ii)&#x000a0;if registered, are they marketed at affordable prices? We also obtained information about the therapeutic relevance of the new products from the databases of two independent drug bulletins.</p></sec><sec sec-type="methods"><title>Methods</title><p>This is a cross-sectional study. We obtained the list of new products approved by the United States Food and Drug Administration (FDA) in 2011 and 2012.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="R3" ref-type="bibr"><sup>3</sup></xref> One product, Gadobutrol (Gadovist), was approved during the study period but excluded from the study because it is a contrast dye used in radiology, not a pharmaceutical treatment. The FDA&#x02019;s medical reviews of the new products, included in their drug approval history,<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> provided the names of countries where the trials had been conducted. If this information was not available in the medical reviews, we obtained it from the trial sponsors.</p><sec><title>Obtaining regulatory status</title><p>We searched the pharmaceutical registers for the regulatory status of relevant products in each country. The information included in the registers varies slightly by country. Brazil, Chile and Colombia maintain a register of approved pharmaceuticals; Argentina has a register of marketed products; Mexico publishes a list of the products approved per time period and Peru catalogues products available in pharmacies (See <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref> for a list of web sites consulted). For the countries without registers (Costa Rica, Ecuador, Panama, Peru, Uruguay) we approached the regulatory agencies. We were unable to reach the regulators in the Dominican Republic or the Bolivarian Republic of Venezuela.</p><boxed-text id="B1" position="float" orientation="portrait"><label>Box&#x000a0;1</label><caption><title>Databases consulted to obtain registration status of drugs tested and the price of pharmaceuticals </title></caption><sec><title>Argentina</title><list list-type="bullet" id="L1"><list-item><p>Vademecum Nacional de Medicamentos, ANMAT<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p></list-item><list-item><p>Listado Oficial de Medicamentos Comercializados LOMAC, ANMAT<xref rid="R6" ref-type="bibr"><sup>6</sup></xref></p></list-item></list></sec><sec><title>Brazil</title><list list-type="bullet" id="L2"><list-item><p>Drug price list, Ag&#x000ea;ncia Nacional de Vigil&#x000e2;ncia Sanit&#x000e1;ria<xref rid="R7" ref-type="bibr"><sup>7</sup></xref></p></list-item><list-item><p>Medications that have been analysed, Ag&#x000ea;ncia Nacional de Vigil&#x000e2;ncia Sanit&#x000e1;ria<xref rid="R8" ref-type="bibr"><sup>8</sup></xref></p></list-item></list></sec><sec><title>Chile</title><list list-type="bullet" id="L3"><list-item><p>Query system of registered products, Instituto de Salud P&#x000fa;blica<xref rid="R12" ref-type="bibr"><sup>12</sup></xref></p></list-item><list-item><p>Pharmaceucial prices, Precio de Remedios<xref rid="R13" ref-type="bibr"><sup>13</sup></xref></p></list-item></list></sec><sec><title>Colombia</title><list list-type="bullet" id="L4"><list-item><p>Product data - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)<xref rid="R9" ref-type="bibr"><sup>9</sup></xref></p></list-item><list-item><p>List of chemical entities with unpublished information protected by Decree 2085 of 2002 - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)<xref rid="R10" ref-type="bibr"><sup>10</sup></xref></p></list-item><list-item><p>Drug price &#x02013; Circular 2, 2012, Ministerio de Salud y Protecci&#x000f3;n Social<xref rid="R11" ref-type="bibr"><sup>11</sup></xref></p></list-item></list></sec><sec><title>Mexico</title><list list-type="bullet" id="L5"><list-item><p>Price list, Ministry of Economy<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p></list-item><list-item><p>Pharmaceutical prices, Precio de Remedios<xref rid="R15" ref-type="bibr"><sup>15</sup></xref></p></list-item></list></sec><sec><title>Peru</title><list list-type="bullet" id="L6"><list-item><p>Cat&#x000e1;logo de Productos Farmac&#x000e9;uticos, Ministerio de Salud<xref rid="R16" ref-type="bibr"><sup>16</sup></xref>M&#x000f3;dulo de Consulta de Precios, Ministerio de Salud<xref rid="R17" ref-type="bibr"><sup>17</sup></xref></p></list-item></list></sec></boxed-text><p>We contacted pharmaceutical companies&#x02019; headquarters in the United States of America to gather information on the marketing status of their products in the selected countries.</p></sec><sec><title>Cost of medicines</title><p>In Latin America, about 78% of all medicines are paid for out-of-pocket in retail pharmacies.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> Since the products of interest were not included in the World Health Organization (WHO)/Health Action International (HAI) medicine prices&#x02019; database, we obtained the price of the unit dose of each product from the countries&#x02019; price observatories, which report the maximum price to consumers (Brazil, Mexico) or the observed consumer prices (Argentina, Chile, Colombia, Ecuador, Peru; <xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref>).</p><p>The consumer prices for Argentinean products not tracked by its observatory and for products in Costa Rica, where there is no observatory, were provided by pharmacological experts who obtained them from local distributors. The quantities needed to complete a course or a year of treatment were calculated using the FDA-approved product label. The pricing information was gathered between 25 August and 20 September, 2014.</p></sec><sec><title>Commercialization status</title><p>Obtaining information on the commercialization status of each product from the pharmaceutical companies was difficult. The headquarters of some companies responded quickly with the requested information (Vertex, Exelixis, Glaxo Smith Kline (GSK), Bristol-Myers Squibb (BMS), Sanofi, AstraZeneca), while others referred us to their country subsidiaries or to the companies responsible for commercializing their products outside the United States of America (USA). The accuracy of the information provided depended on the familiarity of the respondent with the company&#x02019;s practices and databases. Two companies provided contradictory information and one referred us back and forth between the original producer and the licensee. With few exceptions (Pfizer Brazil, Colombia and Mexico; Janssen Argentina; Novartis Argentina and Colombia; Takeda Brazil and Boehringer Mexico), the Latin American offices were less willing to share information than the respondents at headquarters. One company representative wrote: &#x0201c;In response to your question below, we have a policy of restricting the disclosure of proprietary business information/strategies unless we have a formal business relationship protected by a confidential disclosure agreement.&#x0201d;</p><p>Information on registration status and pricing helped resolve some of the inaccuracies of information reported by industry. For example, pricing information indicated the probable availability of pertuzumab in Mexico, rivaroxavan in Colombia and Mexico and ticagrelor in Argentina. We decided that bosutinib was not marketed in Argentina or Peru since it was not included on the list of marketed products (Argentina) or in the catalogue of products available in pharmacies (Peru) and because price information was not available in either country.</p><p>It was impossible to confirm the marketing status in 10 cases (pasireotide in Brazil; rilpivirine in Argentina, Chile and Mexico; pertuzumab in Peru; teriflunomide in Chile and Mexico; tofacitinib in Costa Rica and Peru; and vandetanib in Mexico).</p></sec><sec><title>Measuring affordability</title><p>There are challenges in gathering information related to the price of medicines and incomes to determine affordability thresholds.<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> Some argue that a threshold of 5% of total expenditure for the purchase of medicines would classify them as unaffordable in countries such as India and Indonesia.<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> Some authors consider health-care expenditure catastrophic if it exceeds 10% of yearly household income.<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> In this study, the affordability of each course of treatment is presented in relation to the monthly household or per capita income. Whether or not this is a catastrophic expenditure depends on the socioeconomic status of the individual or the household. In regions with large income inequalities, such as Latin America, using population averages can be misleading.</p><p>Wealth was measured using: (i)&#x000a0;monthly minimum wages in 2014, obtained from public announcements in the media; (ii)&#x000a0;average monthly per capita income, from a World Bank database; (iii)&#x000a0;the monthly household net adjusted disposable income, and (iv)&#x000a0;the monthly household financial wealth which was only available for Brazil, Chile and Mexico (<xref ref-type="table" rid="T1">Table&#x000a0;1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Monthly minimum wage, monthly income per capita, household net-adjusted disposable income and household financial wealth</title></caption><table frame="hsides" rules="groups"><col width="76" span="1"/><col width="127" span="1"/><col width="104" span="1"/><col width="198" span="1"/><col width="155" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Country</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Monthly minimum wage,<sup>a</sup> US$</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Mean monthly income per capita,<sup>b</sup> US$ </th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Average monthly household net-adjusted disposable income,<sup>c</sup> US$</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Average monthly household financial wealth,<sup>d</sup> US$</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Argentina</td><td valign="top" align="center" rowspan="1" colspan="1">523 (since 9/2014)</td><td valign="top" align="center" rowspan="1" colspan="1">1230</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Brazil</td><td valign="top" align="center" rowspan="1" colspan="1">329 (since 7/2014)</td><td valign="top" align="center" rowspan="1" colspan="1">929</td><td valign="top" align="center" rowspan="1" colspan="1">859</td><td valign="top" align="center" rowspan="1" colspan="1">573</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Chile</td><td valign="top" align="center" rowspan="1" colspan="1">387 (since7/2014)</td><td valign="top" align="center" rowspan="1" colspan="1">1311</td><td valign="top" align="center" rowspan="1" colspan="1">1147</td><td valign="top" align="center" rowspan="1" colspan="1">1512</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Colombia</td><td valign="top" align="center" rowspan="1" colspan="1">306 (since 1/2014)</td><td valign="top" align="center" rowspan="1" colspan="1">652</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ecuador</td><td valign="top" align="center" rowspan="1" colspan="1">340 (since 1/2014)</td><td valign="top" align="center" rowspan="1" colspan="1">477</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mexico</td><td valign="top" align="center" rowspan="1" colspan="1">111 (since 1/2014)</td><td valign="top" align="center" rowspan="1" colspan="1">859</td><td valign="top" align="center" rowspan="1" colspan="1">1071</td><td valign="top" align="center" rowspan="1" colspan="1">871</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Peru</td><td valign="top" align="center" rowspan="1" colspan="1">259 (since 6/2012)</td><td valign="top" align="center" rowspan="1" colspan="1">550</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><p>NA: not available; OECD: Organisation for Economic Co-operation and Development; US$: United States dollars.</p><p><sup>a</sup> The minimum wage per country was obtained from public announcements in the media. Local currencies were exchanged into US$ according to the official exchange rate of 1 September 2014.</p><p><sup>b</sup> Income per capita from the 2013 database of the World Bank adjusted by authors to the mean value.</p><p><sup>c</sup> Household net-adjusted disposable income from the <italic>OECD Better life index 2014</italic>. It is defined as the amount of money that a household earns, or gains, each year after taxes and transfers. It represents the money available to a household for spending on goods or services. The income reported in this publication is for 2011, <ext-link ext-link-type="uri" xlink:href="http://www.oecdbetterlifeindex.org/topics/income/">http://www.oecdbetterlifeindex.org/topics/income/</ext-link>.</p><p><sup>d</sup> Household financial wealth is from the <italic>OECD Better life index 2014</italic>. It is defined as the total value of a household&#x02019;s financial worth, or the sum of its overall financial assets minus liabilities. Financial wealth takes into account: savings, monetary gold, currency and deposits, stocks, securities and loans. The wealth reported in this publication is for 2011, <ext-link ext-link-type="uri" xlink:href="http://www.oecdbetterlifeindex.org/topics/income/">http://www.oecdbetterlifeindex.org/topics/income/</ext-link>.</p></table-wrap-foot></table-wrap><p>Finally, we consulted the databases of two independent drug bulletins (Prescrire, France [<ext-link ext-link-type="uri" xlink:href="http://www.prescrire.org/fr/Search.aspx">http://www.prescrire.org/fr/Search.aspx</ext-link>], and the Health Research Group &#x02013; Public Citizen, USA [<ext-link ext-link-type="uri" xlink:href="http://www.worstpills.org/search/">http://www.worstpills.org/search/</ext-link>]) for assessments of the clinical relevance of the new products compared with existing treatments.</p></sec></sec><sec><title>Findings</title><p>The 33 products included in this study are shown in <xref ref-type="table" rid="T2">Table&#x000a0;2</xref>. Of an expected 114 registrations, if the 33 products had been registered in all the countries where tested, 60% (68/114) were completed. Three cases were excluded as the regulatory status of the product could not be determined by 20 September 2014.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Products approved by the United States Food and Drug Administration in 2011 and 2012 that were tested in pivotal trials in Latin America</title></caption><table frame="hsides" rules="groups"><col width="154" span="1"/><col width="101" span="1"/><col width="106" span="1"/><col width="226" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Non-proprietary name</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Commercial name</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Pharmaceutical company</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Countries where pivotal clinical trials were conducted</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aclidium bromide</td><td valign="top" align="left" rowspan="1" colspan="1">Tudorza Pressair&#x000ae;/Eklaire Genuari&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Forest/Almirall</td><td valign="top" align="left" rowspan="1" colspan="1">Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aflibercept</td><td valign="top" align="left" rowspan="1" colspan="1">Eylea&#x000ae;/Eylia&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Bayer</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Colombia, Mexico</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Apixaban</td><td valign="top" align="left" rowspan="1" colspan="1">Eliquis&#x000ae;/Elicuis&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">BMS</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Colombia, Mexico, Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Axitinib</td><td valign="top" align="left" rowspan="1" colspan="1">Inlyta&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Azilsartan, medoxomil</td><td valign="top" align="left" rowspan="1" colspan="1">Edarbi&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Takeda</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Chile, Mexico, Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bedaquiline</td><td valign="top" align="left" rowspan="1" colspan="1">Sirturo&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Janssen</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Belatacept</td><td valign="top" align="left" rowspan="1" colspan="1">Nulojix&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">BMS</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Mexico,</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Belimumab</td><td valign="top" align="left" rowspan="1" colspan="1">Benlysta&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">GSK</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bosutinib</td><td valign="top" align="left" rowspan="1" colspan="1">Bosulif&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Colombia, Mexico, Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cabozantinib</td><td valign="top" align="left" rowspan="1" colspan="1">Cometriq&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Exelixis/Sobi</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil, Chile, Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Crizotinib</td><td valign="top" align="left" rowspan="1" colspan="1">Xalkori&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Elvitegravir/obicistat/ emtricitabine/tenofovir disoproxil fumarate</td><td valign="top" align="left" rowspan="1" colspan="1">Stribild&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Gilead</td><td valign="top" align="left" rowspan="1" colspan="1">Mexico</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Enzalutamide</td><td valign="top" align="left" rowspan="1" colspan="1">Xtandi&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Raffo/Astellas</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Chile</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ezogabine</td><td valign="top" align="left" rowspan="1" colspan="1">Potiga&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">GSK</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Mexico</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Indacaterol maleate</td><td valign="top" align="left" rowspan="1" colspan="1">Arcapta Neohaler&#x000ae;/Onbrize&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Novartis</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Chile, Colombia, Ecuador, Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ipilimumab</td><td valign="top" align="left" rowspan="1" colspan="1">Yerboy&#x000ae;/Yervoy&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">BMS</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Linagliptin</td><td valign="top" align="left" rowspan="1" colspan="1">Tradjenta&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Boehringer</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Mexico</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lucinactant</td><td valign="top" align="left" rowspan="1" colspan="1">Surfaxin&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Discovery</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil, Chile, Ecuador, Mexico, Panama, Uruguay</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pasireotide</td><td valign="top" align="left" rowspan="1" colspan="1">Signifor&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Novartis</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Mexico</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Perampanel</td><td valign="top" align="left" rowspan="1" colspan="1">Fycompa&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Eisai</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Chile, Mexico</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pertuzumab</td><td valign="top" align="left" rowspan="1" colspan="1">Perjeta&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Genentech/Roche</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil, Mexico, Peru</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Regorafenib</td><td valign="top" align="left" rowspan="1" colspan="1">Stivarga&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Bayer</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rilpivirine</td><td valign="top" align="left" rowspan="1" colspan="1">Edurant&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Janssen</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Costa Rica, Mexico, Panama</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">Xarelto&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Bayer/Janssen</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela (Bolivarian Republic of)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Roflumilast</td><td valign="top" align="left" rowspan="1" colspan="1">Daliresp&#x000ae;/Daxas&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Forest/Takeda</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Taliglucerase alfa</td><td valign="top" align="left" rowspan="1" colspan="1">Elelyso&#x000ae;/Uplyso&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer</td><td valign="top" align="left" rowspan="1" colspan="1">Chile</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tbo-filgastrim</td><td valign="top" align="left" rowspan="1" colspan="1">Neutroval&#x000ae;/Granix&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Teva</td><td valign="top" align="left" rowspan="1" colspan="1">Brazil, Chile</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Telaprevir</td><td valign="top" align="left" rowspan="1" colspan="1">Incivek&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Janssen/Vertex</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Teriflunomide</td><td valign="top" align="left" rowspan="1" colspan="1">Aubagio&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Genzyme</td><td valign="top" align="left" rowspan="1" colspan="1">Chile, Colombia</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ticagrelor</td><td valign="top" align="left" rowspan="1" colspan="1">Brilinta&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">AstraZeneca</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Mexico,</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tofacitinib</td><td valign="top" align="left" rowspan="1" colspan="1">Xeljan&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Pfizer</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Mexico, Peru, Venezuela (Bolivarian Republic of)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vandetanib</td><td valign="top" align="left" rowspan="1" colspan="1">Caprelsa&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">AstraZeneca</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Mexico</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ziv-aflibercept</td><td valign="top" align="left" rowspan="1" colspan="1">Zaltrap&#x000ae;</td><td valign="top" align="left" rowspan="1" colspan="1">Sanofi</td><td valign="top" align="left" rowspan="1" colspan="1">Argentina, Brazil, Chile, Colombia, Mexico</td></tr></tbody></table></table-wrap><p>Combining information on registration and availability indicated that 30% (10/33) of products were not registered or commercialized in any of the countries where they had been tested (aclidium bromide, axitinib, bedaquiline, bosutinib, cabozantinib, elvitegravir/obicistat/emtricitabine/tenofovir disoproxil fumarate, lucinactant, perampanel, tbo-filgastrim, ziv-aflibercept); two products were registered but not marketed in any of the countries where tested (enzalutamide and ezogabine) and eight were registered and commercialized in all countries where tested (aflibercept, indacaterol maleate, ipilimumab, linagliptin, regorafenib, roflumilast, taliglucerase alfa, telaprevir).</p><p><xref ref-type="table" rid="T3">Table&#x000a0;3</xref> presents the approval and commercialization status in September 2014 of the products included in the study that were not registered or commercialized in all the countries where tested. In two cases the pharmaceutical company stated that a product was available when the regulatory agency said it had not been approved and in several cases the products were registered but not marketed. In total, by September 2014, 36.4% of products were not marketed in any of the countries where they were tested and only 51% were available where tested.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Approval and marketing status in September 2014 of products tested in Latin American countries and approved by the FDA in 2011 and 2012<sup>a</sup></title></caption><table frame="hsides" rules="groups"><col width="90" span="1"/><col width="69" span="1"/><col width="64" span="1"/><col width="11" span="1"/><col width="69" span="1"/><col width="63" span="1"/><col width="11" span="1"/><col width="69" span="1"/><col width="64" span="1"/><col width="11" span="1"/><col width="69" span="1"/><col width="63" span="1"/><col width="11" span="1"/><col width="69" span="1"/><col width="63" span="1"/><col width="11" span="1"/><col width="69" span="1"/><col width="63" span="1"/><col width="11" span="1"/><col width="69" span="1"/><col width="63" span="1"/><col width="11" span="1"/><col width="69" span="1"/><col width="63" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Non-proprietary name</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Argentina<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Brazil<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Chile<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Colombia<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Costa Rica<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Mexico<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Panama<hr/></th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"/><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">Peru<hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">R</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">M</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">R</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">M</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">R</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">M</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">R</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">M</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">R</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">M</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">R</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">M</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">R</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">M</th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">R</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">M</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Apixaban</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA<sup>b</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Azilsartan medoxomil</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Belatacept</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Belimumab</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">A</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Crizotinib</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Enzalutamide</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ezogabine</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pasireotide</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pertuzumab</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rilpivirine</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Teriflunomide</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ticagrelor</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tofacitinib</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">C<sup>c</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">C</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vandetanib</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">FA</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><p>A:&#x02009;available; C:&#x02009;received contradictory information; FA:&#x02009;failed to get an answer; FDA: (United States) Food and Drug Administration; M: marketing status; NA:&#x02009;not available; R: registered.</p><p><sup>a</sup> The table does not include the eight new products that have been registered and commercialized in all the countries; neither does it include the ten new products that have not been registered or commercialized in any country.</p><p><sup>b</sup> BMS said that apixaban was not marketed in Mexico but we found its price. It may only be available for compassionate use.</p><p><sup>c</sup> The Caja Costarricense de Seguridad Social, the social security agency that provides health care including free medications to 90% of the Costa Rica&#x02019;s population, has not bought tofacitinib and it is not available in major pharmacies.</p><p>Note: For cells with no information, no clinical trials with this product were conducted in the country.</p></table-wrap-foot></table-wrap><p>The cost of one course of treatment (or a year of treatment for chronic conditions) is shown in <xref ref-type="table" rid="T4">Table&#x000a0;4</xref>. The prices of 18 of the 21 products marketed in Latin American countries for which we were able to obtain information varied widely. In all countries, and for all except one of the products, the cost was greater than the monthly minimum wage. Five products cost one to four times the monthly minimum wage, while six cost between 100 and 896 times this amount.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Cost of a course of treatment (or a year of treatment for chronic conditions) for new products tested in Latin America in relation to the monthly minimum wage, 2014</title></caption><table frame="hsides" rules="groups"><col width="90" span="1"/><col width="101" span="1"/><col width="132" span="1"/><col width="130" span="1"/><col width="79" span="1"/><col width="71" span="1"/><col width="79" span="1"/><col width="79" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Cost<sup>a</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Argentina</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Brazil</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Chile</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Colombia</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Ecuador</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Mexico</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Peru</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x0003c;&#x02009;1</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1&#x02013;4</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Indacaterol, Linagliptin, Ticagrelor</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Roflumilast, Ticagrelor</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Indacaterol</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Indacaterol</td><td valign="top" align="left" rowspan="1" colspan="1">Indacaterol</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">5&#x02013;9</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Belatacept</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Azilsartan, Linagliptin</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">10&#x02013;19</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Belimumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Ticagrelor</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">20&#x02013;39</td><td valign="top" align="left" rowspan="1" colspan="1">Aflibercept, Regorafenib</td><td valign="top" align="left" rowspan="1" colspan="1">Aflibercept</td><td valign="top" align="left" rowspan="1" colspan="1">Aflibercept</td><td valign="top" align="left" rowspan="1" colspan="1">Aflibercept</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">40&#x02013;59</td><td valign="top" align="left" rowspan="1" colspan="1">Belatacept, Tofacitinib</td><td valign="top" align="left" rowspan="1" colspan="1">Belimumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Tofacitinib</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">60&#x02013;99</td><td valign="top" align="left" rowspan="1" colspan="1">Telaprevir</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">100&#x02013;149</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Telaprevir</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">150&#x02013;200</td><td valign="top" align="left" rowspan="1" colspan="1">Pasireotide</td><td valign="top" align="left" rowspan="1" colspan="1">Pertuzumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Tofacitinib</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">201&#x02013;896</td><td valign="top" align="left" rowspan="1" colspan="1">Ipilimumab, Vandetanib</td><td valign="top" align="left" rowspan="1" colspan="1">Ipilimumab, Vandetanib</td><td valign="top" align="left" rowspan="1" colspan="1">Ipilimumab, Taliglucerase alfa</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Pasireotide, Pertuzumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Multiple of average monthly per capita income.</p><p>Note: Information about income is available in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>.</p></table-wrap-foot></table-wrap><p>Three products in Argentina and Chile &#x02013; and two products in Brazil &#x02013; cost less than the average monthly per capita income (<xref ref-type="table" rid="T5">Table&#x000a0;5</xref>). Only one product (rivaroxavan) cost less than the average monthly per capita income in all countries, but four products cost more than 100 times this amount. The results using monthly household disposable income and monthly household wealth were very similar to findings for average monthly per capita income (details available from the corresponding author).</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Cost of a course of treatment (or a year of treatment for chronic conditions) for new products tested in Latin America in relation to average monthly per capita income, 2014</title></caption><table frame="hsides" rules="groups"><col width="44" span="1"/><col width="77" span="1"/><col width="80" span="1"/><col width="82" span="1"/><col width="77" span="1"/><col width="70" span="1"/><col width="77" span="1"/><col width="77" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Cost<sup>a</sup></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Argentina</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Brazil</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Chile</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Colombia</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Ecuador</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Mexico</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Peru</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x0003c;&#x02009;1</td><td valign="top" align="left" rowspan="1" colspan="1">Indacaterol, Linagliptin, Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan, Roflumilast</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Indacaterol, Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td><td valign="top" align="left" rowspan="1" colspan="1">Rivaroxavan</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">1&#x02013;4</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Ticagrelor</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Ticagrelor</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Indacaterol</td><td valign="top" align="left" rowspan="1" colspan="1">Indacaterol</td><td valign="top" align="left" rowspan="1" colspan="1">Apixaban, Azilsartan, Linagliptin, Ticagrelor</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">5&#x02013;9</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Belatacept</td><td valign="top" align="left" rowspan="1" colspan="1">Aflibercept, Belimumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">10&#x02013;19</td><td valign="top" align="left" rowspan="1" colspan="1">Regorafenib</td><td valign="top" align="left" rowspan="1" colspan="1">Aflibercept, Belimumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Aflibercept</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">20&#x02013;39</td><td valign="top" align="left" rowspan="1" colspan="1">Aflibercept, Belatacept, Tofacitinib</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Tofacitinib</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Tofacitinib</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">40&#x02013;59</td><td valign="top" align="left" rowspan="1" colspan="1">Telaprevir</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">60&#x02013;99</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Ipilimumab, Pertuzumab, Telaprevir</td><td valign="top" align="left" rowspan="1" colspan="1">Ipilimumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Pertuzumab</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">100&#x02013;149</td><td valign="top" align="left" rowspan="1" colspan="1">Ipilimumab, Pasireotide</td><td valign="top" align="left" rowspan="1" colspan="1">Pasireotide</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">150&#x02013;200</td><td valign="top" align="left" rowspan="1" colspan="1">Vandetanib</td><td valign="top" align="left" rowspan="1" colspan="1">Vandetanib</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">201&#x02013;203</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Taliglucerase alfa</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Multiple of average monthly per capita income.</p><p>Note: Information about income is available in <xref ref-type="table" rid="T1">Table&#x000a0;1</xref>.</p></table-wrap-foot></table-wrap><p>The bulletins of Prescrire and/or the Health Research Group evaluated 25 of the 32 products and determined that 20 (80%) had no advantage over existing treatments and had significant side-effects. According to these sources, and other bulletins reviewed by Prescrire, the remaining five products (crizotinib, enzalutamide, ipilimumab, pasireotide, telaprevir) may provide some therapeutic benefit to a subset of patients, but the risk&#x02013;benefit ratio was uncertain (details available from the corresponding author).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>According to our data, 20 months after the FDA had approved the commercialization of 33 products in the USA, only eight (25%) had been registered and commercialized in all the Latin American countries where they had been tested. Thirty percent (10/33) had been neither registered nor commercialized in any of the countries; 45% (15/33) were registered and some of these were commercialized in several countries.</p><p>The suboptimal implementation of differential or tiered pricing for pharmaceuticals, a strategy recommended by WHO to enhance access to pharmaceuticals,<xref rid="R22" ref-type="bibr"><sup>22</sup></xref> has led to arbitrary decisions. For example, the antiretroviral drug atazanavir is supplied for free to people living with human immunodeficiency virus in Peru. The country pays about 6.34 United States dollars (US$) per tablet while Argentina pays US$&#x000a0;3.04, Brazil US$&#x000a0;1.00 and the Plurinational State of Bolivia US$&#x000a0;0.48 (personal communication), prices that with the exception of the Plurinational State of Bolivia do not correspond to the wealth of the countries. It is conceivable that the establishment of national or public health sector affordability thresholds would render new pharmaceuticals accessible.</p><p>Within pharmaceutical companies, there seems to be little communication between the research and development units and those responsible for marketing the final products. Clinical trials are outsourced when the countries meet the conditions of the sponsor or of the contract research organizations managing the trial, such as having large urban centres with researchers willing to enrol patients, expedited approval of protocols and sufficient patients who can be readily recruited.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> The registration and marketing of new products are business decisions based on a country&#x02019;s regulatory conditions, the presence of a business affiliate or partner, the willingness of the health system to include a product in its formulary, the number of patients who can afford the treatment and estimates of drug profitability for the company.</p><p>Latin American agencies responsible for the approval of clinical trials, including the research ethics committees, do not consider if the tested products will be available and affordable. Only Brazil requires that all drugs tested in the country be registered when found to be safe and effective. Resolution 446 of its regulatory agency (Anvisa) reads: &#x0201c;When developing new drugs, if safety and effectiveness is proven, its registration is obligatory in Brazil.&#x0201d; However, as our findings demonstrate, it appears that the regulation is not being enforced.</p><p>In sum, neither the sponsors of the clinical trials, nor the regulatory agencies, nor any of the bodies that approved ethical declarations regarding clinical trials have suggested pre-trial mechanisms to ensure that new products will be available and affordable in those countries where testing has taken place. Without such mechanisms, declarations such as those of the Council for International Organizations of Medical Sciences (CIOMS), the Universal Declaration on Bioethics and Human Rights, or the Declaration of Helsinki are difficult to fulfil (<xref ref-type="boxed-text" rid="B2">Box&#x000a0;2</xref>). International Ethical Guidelines for Biomedical Research Involving Human Subjects state that:</p><boxed-text id="B2" position="float" orientation="portrait"><label>Box&#x000a0;2</label><caption><title>International ethical guidelines asserting that post trial access to treatment should be ensured</title></caption><sec><title>Council for International Organizations of Medical Sciences<xref rid="R24" ref-type="bibr"><sup>24</sup></xref></title></sec><sec><title>Guideline 10: Research in populations and communities with limited resources</title><p>Before undertaking research in a population or community with limited resources, the sponsor and the investigator must make every effort to ensure that:</p><list list-type="bullet" id="L7"><list-item><p>the research is responsive to the health needs and the priorities of the population or community in which it is to be carried out; and</p></list-item><list-item><p>any intervention or product developed, or knowledge generated, will be made reasonably available for the benefit of that population or community.</p></list-item></list></sec><sec><title>Commentary on Guideline 10</title><p>This is applicable especially to research conducted in countries where governments lack the resources to make such products or benefits widely available. Even when a product to be tested in a particular country is much cheaper than the standard treatment in some other countries, the government or individuals in that country may still be unable to afford it. If the knowledge gained from the research in such a country is used primarily for the benefit of populations that can afford the tested product, the research may rightly be characterized as exploitative and, therefore, unethical.</p><p>The negotiation should cover the health-care infrastructure required for safe and rational use of the intervention, the likelihood of authorization for distribution and decisions regarding payments, royalties, subsidies, technology and intellectual property, as well as distribution costs, when this economic information is not proprietary.</p><p>In general, if there is good reason to believe that a product developed or knowledge generated by research is unlikely to be reasonably available to, or applied to the benefit of, the population of a proposed host country or community after the conclusion of the research, it is unethical to conduct the research in that country or community.</p></sec><sec><title>Universal Declaration on Bioethics and Human Rights. Article 15 &#x02013; Sharing of benefits<xref rid="R25" ref-type="bibr"><sup>25</sup></xref></title><p>Benefits resulting from any scientific research and its applications should be shared with society as a whole and within the international community, in particular with developing countries.</p></sec><sec><title>Declaration of Helsinki (2013)<xref rid="R26" ref-type="bibr"><sup>26</sup></xref></title><p>Item 22. In clinical trials, the protocol must also describe appropriate arrangements for post-trial provisions.</p></sec></boxed-text><disp-quote><p>&#x0201c;In general, if there is good reason to believe that a product developed or knowledge generated by research is unlikely to be reasonably available to, or applied to the benefit of the population of a proposed host country or community after the conclusion of the research, it is unethical to conduct the research in the country or community.&#x0201d;(Commentary on Guideline&#x000a0;10).<xref rid="R27" ref-type="bibr"><sup>27</sup></xref></p></disp-quote><p>Latin American regulatory agencies have very limited resources for assessing the safety and efficacy of new products, some of which are very complex. For this reason, they depend on the FDA or the European Medicines Agency&#x02019;s decisions to grant approval. The pharmaceutical industry claims that conducting trials in Latin America strengthens research capacity in biomedical science,<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> but it could also be suggested that high payments to principal investigators lure some of them away from developing other products needed in the region, such as treatments for dengue, malaria and leishmaniasis or from the development of generic biophamaceuticals, a move that could save lives and money.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="R29" ref-type="bibr"><sup>29</sup></xref> Industry prices are not related to product development cost<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R31" ref-type="bibr"><sup>31</sup></xref> and some new products are unaffordable even in high-income countries. In both the USA and the United Kingdom of Great Britain and Northern Ireland,<xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>&#x02013;</sup><xref rid="R35" ref-type="bibr"><sup>35</sup></xref> physicians and health authorities are increasingly reluctant to accept expensive medications offering little improvement over existing cheaper alternatives with demonstrated safety and efficacy.</p><p>In January 2014, a new consensus framework for ethical collaboration between patients&#x02019; organizations, health-care professionals and the pharmaceutical industry was published.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref> The framework states that:</p><disp-quote><p>&#x0201c;Continuing to advocate and support the principle that all human subject research must have legitimate scientific purpose, aims to improve health outcomes and be ethically conducted&#x02026;&#x0201d;<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></p></disp-quote><p>To comply with this consensus and with universally-accepted ethical principles,<xref rid="R27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="R37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="R38" ref-type="bibr"><sup>38</sup></xref> the pharmaceutical industry should: (i)&#x000a0;reconsider research and commercial strategies to ensure that new products add therapeutic value to the existing therapeutic arsenal at an affordable price; (ii)&#x000a0;include the estimated local prices for potential new products in clinical trial protocols so that the regulatory agencies and research ethics committees can consider the affordability of the product when authorizing the research (iii)&#x000a0; work with regulatory agencies in the countries where products are tested to ensure registration and availability of new products that prove to be safe and effective.</p><sec><title>Study limitations</title><p>The information on registration and commercialization status of new products may contain inaccuracies. We identified and corrected some errors through triangulation, but others may not have been detected. Some FDA reviews did not specify which of the clinical trials were pivotal. Even though we also gathered information from trial sponsors, we may have included trials that technically might not be considered pivotal. There are unavoidable limitations in estimating thresholds of affordability, since financial sacrifices and risks cannot be easily defined by others. These are personal decisions that are influenced by personal values and culture.</p><p>Evaluating the price of drugs continues to be complex and currently there is no standard method. Despite their shortcomings, country observatories, which tend to be based on the WHO/HAI methods, are probably the best and most reliable sources of information. Currency variations add to the complexity of reporting pricing information across countries. We priced the drugs in September 2014, but the data used to determine monthly income is from 2013. Moreover, in the Latin American countries included in this study, income is very poorly distributed. If we were to remove the highest two income deciles, the income per capita for the rest of the population would be drastically reduced, and therefore the affordability threshold would have to be lowered.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Many pharmaceutical products tested in Latin America are unavailable and/or unaffordable to most of the population and add little therapeutic value compared to existing treatments. There is an urgent need to determine the public-sector affordability thresholds for new pharmaceutical products, and efforts should be made to ensure that ethics committees can take into consideration the affordability and clinical relevance of the new products in their assessment of the clinical trial protocols. The products included in this study did not respond to the most pressing medical needs of people in the region and may have diverted scientific resources from addressing issues of higher relevance. While governments welcome the investments that accompany foreign trials, it is important to document their opportunity costs.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank Mart&#x000ed;n Ca&#x000f1;as (Argentina), Corina Bontempo Duca de Freitas (Brasil), Andrea Carolina Reyes Rojas and Oscar And&#x000ed;a (Colombia), Marv&#x000ed;n G&#x000f3;mez (Costa Rica), Bel&#x000e9;n Mena (Ecuador), Rogelio Fern&#x000e1;ndez (M&#x000e9;xico) and Alarico Rodr&#x000ed;guez (Uruguay). Also, Iain Chalmers, Donald Light, Pauline Rosenau and Bruno Schlemper Junior.</p></ack><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="web">The 2014 drug trend report. St. Louis: The express scripts holding company; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://lab.express-scripts.com/drug-trend-report">http://lab.express-scripts.com/drug-trend-report</ext-link> [cited 2015 May 11].</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="web">2011 novel new drugs. Silver Spring: Center for Drug Evaluation and Research, US Food and Drug Administration; 2012. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM293663.pdf">http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM293663.pdf</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 11].</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="web">New molecular entity approvals for 2012 [Internet]. Silver Spring: US Food and Drug Administration; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm336115.htm">http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm336115.htm</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 11].</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="web">Drugs@FDA [Internet]. Silver Spring: US Food and Drug Administration; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 15].</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="web">Vademecum Nacional de Medicamentos [Internet]. Buenos Aires, ANMAT, 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://anmatvademecum.servicios.pami.org.ar/index.html">http://anmatvademecum.servicios.pami.org.ar/index.html</ext-link> [cited 2015 May 27]. Spanish.</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="web">Listado Oficial de Medicamentos Comercializados [Internet]. Buenos Aires, ANMAT, 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://anmatvademecum.servicios.pami.org.ar/index.html">http://anmatvademecum.servicios.pami.org.ar/index.html</ext-link> [cited 2015 May 27]. Spanish.</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="web">Listas de Pre&#x000e7;os de Medicamentos [Internet]. Bras&#x000ed;lia: Ag&#x000ea;ncia Nacional de Vigil&#x000e2;ncia Sanit&#x000e1;ria; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://tinyurl.com/nwe9go4">http://tinyurl.com/nwe9go4</ext-link> [cited 2015 May 15]. Portuguese.</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="web">Medicamentos Analisados [Internet]. Bras&#x000ed;lia: Ag&#x000ea;ncia Nacional de Vigil&#x000e2;ncia Sanit&#x000e1;ria; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.anvisa.gov.br/datavisa/fila_medicamento/index.asp">http://www.anvisa.gov.br/datavisa/fila_medicamento/index.asp</ext-link> [cited 2015 May 15]. Portuguese.</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="web">Consulta Datos de Productos [Internet]. Bogota (Colombia): INVIMA; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://web.sivicos.gov.co:8080/consultas/consultas/consreg_encabcum.jsp">http://web.sivicos.gov.co:8080/consultas/consultas/consreg_encabcum.jsp</ext-link> [cited 2015 May 15]. Spanish.</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="web">Listado de entidades qu&#x000ed;micas con informaci&#x000f3;n no divulgada protegida seg&#x000fa;n el Decreto 2085 de 2002 corte a 31 de Julio de 2014 [Internet]. Bogota (Colombia): INVIMA; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.invima.gov.co/images/pdf/tramites-y-servicios/moleculas-protegidas/Listado%20de%20entidades%20quimicas%20protegidas%20a%2031%20de%20Julio.pdf">https://www.invima.gov.co/images/pdf/tramites-y-servicios/moleculas-protegidas/Listado%20de%20entidades%20quimicas%20protegidas%20a%2031%20de%20Julio.pdf</ext-link> [cited 2015 May 15]. Spanish.</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="web">Precios de Medicamentos - Circular 2 de 2012 Excel [Internet]. Bogot&#x000e1;: Ministerio de Salud y Protecci&#x000f3;n Social; 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.sispro.gov.co/recursosapp/app/Pages/Precios%20de%20Medicamentos%20-%20Circular%202%20de%202012%20Excel.aspx">http://www.sispro.gov.co/recursosapp/app/Pages/Precios%20de%20Medicamentos%20-%20Circular%202%20de%202012%20Excel.aspx</ext-link> [cited 2015 Mar 15]. Spanish.</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="web">Sistema de consulta de productos registrados [Internet]. Santiago: Instituto de Salud P&#x000fa;blica de Chile; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://registrosanitario.ispch.gob.cl/">http://registrosanitario.ispch.gob.cl/</ext-link> [cited 2015 May 15]. Spanish.</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="web">Precios de Remedios &#x02013; Chile [Internet]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.preciosderemedios.cl/">http://www.preciosderemedios.cl/</ext-link> [cited 2014 August 18]. Spanish.</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="web">Precios registrados de medicamentos con patente vigente. Mexico DF: Ministerio de Economia; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.economia.gob.mx/files/transparencia/focalizada/lista_precios_maximos_medicamentos_de_patente_2014_0829.xls">http://www.economia.gob.mx/files/transparencia/focalizada/lista_precios_maximos_medicamentos_de_patente_2014_0829.xls</ext-link> [cited 2015 May 25].</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="web">Precios de Remedios &#x02013; Mexico [Internet]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.preciosderemedios.mx">http://www.preciosderemedios.mx</ext-link> [cited 2014 September 8]. Spanish.</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="web">Cat&#x000e1;logo de Productos Farmac&#x000e9;uticos. Lima: Ministerio de Salud Peru; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://observatorio.digemid.minsa.gob.pe/Precios/ProcesoL/Catalogo/CatalogoProductos.aspx?over=1">http://observatorio.digemid.minsa.gob.pe/Precios/ProcesoL/Catalogo/CatalogoProductos.aspx?over=1</ext-link> [cited 2015 May 25]. Spanish.</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="web">M&#x000f3;dulo de Consulta de Precios. Lima: Ministerio de Salud Peru; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://observatorio.digemid.minsa.gob.pe">http://observatorio.digemid.minsa.gob.pe</ext-link> [cited 2015 May 25]. Spanish.</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="book"><collab>PAHO</collab>. <source>Health systems and social protection in health.</source>
<publisher-loc>Washington</publisher-loc>: <publisher-name>Pan American Health Organization</publisher-name>; <year>2012</year>.</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Ni&#x000eb;ns</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Brouwer</surname>
<given-names>WBF</given-names></string-name>. <article-title>Measuring the affordability of medicines: importance and challenges.</article-title>
<source>Health Policy</source>. <year>2013</year>
<month>9</month>;<volume>112</volume>(<issue>1-2</issue>):<fpage>45</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.healthpol.2013.05.018</pub-id><pub-id pub-id-type="pmid">23827263</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Ni&#x000eb;ns</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Van de Poel</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Cameron</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ewen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Laing</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Brouwer</surname>
<given-names>WB</given-names></string-name>. <article-title>Practical measurement of affordability: an application to medicines.</article-title>
<source>Bull World Health Organ</source>. <year>2012</year>
<month>3</month>
<day>1</day>;<volume>90</volume>(<issue>3</issue>):<fpage>219</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.10.084087</pub-id><pub-id pub-id-type="pmid">22461717</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="book">O'Donnell O, van Doorslaer E, Wagstaff A, Lindelow M. Analyzing health equity using household survey data: a guide to techniques and their implementation. Washington: World Bank; 2008. Available from: <ext-link ext-link-type="uri" xlink:href="http://siteresources.worldbank.org/INTPAH/Resources/Publications/459843-1195594469249/HealthEquityFINAL.pdf">http://siteresources.worldbank.org/INTPAH/Resources/Publications/459843-1195594469249/HealthEquityFINAL.pdf</ext-link> [cited 2015 May 11].</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="web">Trade, foreign policy, diplomacy and health: access to medicines. Geneva: World Health Organization; 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/trade/glossary/story002/en/">http://www.who.int/trade/glossary/story002/en/</ext-link> [cited 2015 May 12].</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="book"><string-name><surname>Homedes</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Ugalde</surname>
<given-names>A</given-names></string-name>. <chapter-title>Globalization and clinical research in Latin America.</chapter-title> In: <string-name><surname>Homedes</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Ugalde</surname>
<given-names>A</given-names></string-name>, editors. <source>Clinical trials in Latin America: where ethics and business clash.</source>
<publisher-loc>Dordrecht</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2014</year> pp. <fpage>55</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-01363-3_3</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="web">Council for International Organizations of Medical Sciences, World Health Organization. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS, 2002. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cioms.ch/publications/layout_guide2002.pdf">http://www.cioms.ch/publications/layout_guide2002.pdf</ext-link> [cited 2015 May 25].</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="web">Universal Declaration on Bioethics and Human Rights. Paris: UNESCO General Assembly. October 19, 2005. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.unesco.org/new/en/social-and-human-sciences/themes/bioethics/bioethics-and-human-rights/">http://www.unesco.org/new/en/social-and-human-sciences/themes/bioethics/bioethics-and-human-rights/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 Sept 1].</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="web">World Medical Association. Declaration of Helsinki. Fortaleza, Brasil. 64th WMA General Assembly. October 2013. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.wma.net/en/30publications/10policies/b3/">http://www.wma.net/en/30publications/10policies/b3/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 Sept 1]. </mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="web">International ethical guidelines for biomedical research involving human subjects. Geneva: Council for International Organizations of Medical Sciences; 2002. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cioms.ch/publications/layout_guide2002.pdf">http://www.cioms.ch/publications/layout_guide2002.pdf</ext-link> [cited 2015 May 12].</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><collab>ICDRA.</collab>
<article-title>Es el momento de actuar: aseguren el acceso a productos bio-terap&#x000e9;uticos asequibles. Declaraci&#x000f3;n de la Sociedad Civil para pre-ICDRA e ICDRA.</article-title>
<source>Bolet&#x000ed;n F&#x000e1;rmacos</source>. <year>2014</year>;<volume>17</volume>(<issue>4</issue>):<fpage>81</fpage>&#x02013;<lpage>2</lpage>. <comment>Spanish.</comment></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Calder&#x000f3;n</surname>
<given-names>JM</given-names></string-name>. <article-title>Carta abierta al Se&#x000f1;or Presidente de la Rep&#x000fa;blica de Colombia.</article-title>
<source>Bolet&#x000ed;n F&#x000e1;rmacos</source>. <year>2014</year>;<volume>17</volume>(<issue>4</issue>):<fpage>91</fpage>&#x02013;<lpage>2</lpage>. <comment>Spanish.</comment></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="web">Budget-busters: the shift to high-priced innovator drugs in the USA. Boston: EvaluatePharma; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://info.evaluategroup.com/rs/evaluatepharmaltd/images/SV2014.pdf">http://info.evaluategroup.com/rs/evaluatepharmaltd/images/SV2014.pdf</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 12].</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Light</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Warburton</surname>
<given-names>R</given-names></string-name>. <article-title>Demythologizing the high costs of pharmaceutical research.</article-title>
<source>Biosocieties</source>. <year>2011</year>;<volume>6</volume>(<issue>1</issue>):<fpage>34</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1057/biosoc.2010.40</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><collab>Experts in Chronic Myeloid Leukemia</collab>. <article-title>The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.</article-title>
<source>Blood</source>. <year>2013</year>
<month>5</month>
<day>30</day>;<volume>121</volume>(<issue>22</issue>):<fpage>4439</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-03-490003</pub-id><pub-id pub-id-type="pmid">23620577</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="web">Ward A, Neville S. Drug cost watchdog chief calls for honesty with public. Financial Times, August 22, 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ft.com/cms/s/0/c62145a6-2896-11e4-8bda-00144feabdc0.html#axzz3UwNC6Xov">http://www.ft.com/cms/s/0/c62145a6-2896-11e4-8bda-00144feabdc0.html#axzz3UwNC6Xov</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 Sept 1].</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="web">Werth B. A tale of two drugs. MIT Technology review. 2013 Oct 22. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.technologyreview.com/featuredstory/520441/a-tale-of-two-drugs/">http://www.technologyreview.com/featuredstory/520441/a-tale-of-two-drugs/</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 12].</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="web">Steenhuysen J. FDA cancer chief says &#x02018;escalating&#x02019; drug prices can&#x02019;t continue. Reuters. 2014 Jun 1. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.reuters.com/article/2014/06/01/us-health-cancer-fda-idUSKBN0EC13W20140601">http://www.reuters.com/article/2014/06/01/us-health-cancer-fda-idUSKBN0EC13W20140601</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 12].</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="web">Consensus framework for ethical collaboration between patients&#x02019; organisations, healthcare professionals and the pharmaceutical industry. London: International Alliance of Patients&#x02019; Organizations, International Council of Nurses, IFPMA, International Pharmaceutical Federation, World Medical Association; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.wma.net/en/20activities/60campaigns/13consensus/Consensus_Framework-vF.pdf">http://www.wma.net/en/20activities/60campaigns/13consensus/Consensus_Framework-vF.pdf</ext-link><ext-link ext-link-type="uri" xlink:href="http://"/>[cited 2015 May 12]. </mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="book"><source>Universal Declaration on Bioethics and Human Rights.</source>
<publisher-loc>Paris</publisher-loc>: <publisher-name>United Nations Educational, Scientific and Cultural Organization</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><collab>World Medical Association</collab>. <article-title>World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.</article-title>
<source>JAMA</source>. <year>2013</year>
<month>11</month>
<day>27</day>;<volume>310</volume>(<issue>20</issue>):<fpage>2191</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id><pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation></ref></ref-list></back></article>